Proof-of-concept double-blind, placebo-controlled, randomized clinical trial with nilotinib in spondyloarthritis.
Phase of Trial: Phase III
Latest Information Update: 28 Nov 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Spondylarthritis
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 19 Jan 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
- 16 Nov 2011 New source identified and integrated (European Clinical Trials Database).
- 16 Nov 2011 Actual initiation date 21 Apr 2011 added as reported by European Clinical Trials Database.